[1]
|
Berger, J. and Hinglais, N. (1968) Intercapillary Deposits of IgA-IgG. Journal of Urology and Nephrology (Paris), 74, 694-695.
|
[2]
|
Wang, J.Y., He, L.Y., Yan, W.Z., et al. (2020) The Role of Hypertriglyceridemia and Treatment Patterns in the Progression of IgA Nephropathy with a High Proportion of Global Glomerulosclerosis. International Urology and Nephrology, 52, 325-335. https://doi.org/10.1007/s11255-019-02371-3
|
[3]
|
Haas, M. (2005) Histology and Im-munohistology of IgA Nephropathy. Journal of Nephrology, 18, 676-680.
|
[4]
|
蒋文婷, 张红, 李贵森. 无症状性IgA肾病的临床及病理特点分析[J]. 实用医院临床杂志, 2023, 20(3): 36-40.
|
[5]
|
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Man-agement of Glomerular Diseases. Kidney International, 100, S1-S276.
|
[6]
|
Ji, Y., Yang, K., Xiao, B., et al. (2019) Ef-ficacy and Safety of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blocker Therapy for IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Journal of Cellular Biochemistry, 120, 3689-3695. https://doi.org/10.1002/jcb.27648
|
[7]
|
Lv, J.C., Zhang, H., Wong, M.G., et al. (2017) Effect of Oral Methylpred-nisolone on Clinical Outcomes in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA, 318, 432-442.
https://doi.org/10.1001/jama.2017.9362
|
[8]
|
王梦平, 孙健超, 金畅, 董建华, 唐诗韵. 足量泼尼松联合环磷酰胺治疗IgA肾病的疗效及影响因素[J]. 医药导报, 2023: 1-16.
|
[9]
|
Hou, J.-H., Le, W.-B., Chen, N., et al. (2017) Mycophenolate Mofetil Combined with Prednisone versus Full-Dose Prednisone in IgA Nephropathy with Active Pro-liferative Lesions: A Randomized Controlled Trial. American Journal of Kidney Diseases, 69, 788-795. https://doi.org/10.1053/j.ajkd.2016.11.027
|
[10]
|
Pensieri, M.V., Pulvirenti, F., Schiepatti, A., et al. (2019) The High Mortality of Patients with Common Variable Immunodeficiency and Small Bowel Villous Atrophy. Scandinavian Jour-nal of Gastroenterology, 54, 164-168.
https://doi.org/10.1080/00365521.2019.1568543
|
[11]
|
Coppo, R. (2018) The Gut-Renal Connection in IgA Nephropathy. Seminars in Nephrology, 38, 504-512.
https://doi.org/10.1016/j.semnephrol.2018.05.020
|
[12]
|
Floege, J. (2017) Mucosal Corticosteroid Therapy of IgA Nephropathy. Kidney International, 92, 278-280.
https://doi.org/10.1016/j.kint.2017.05.021
|
[13]
|
Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A.B., Renfrow, M.B., Wyatt, R.J., Scolari, F., Mestecky, J., Gharavi, A.G. and Julian, B.A. (2011) The Pathophysiology of IgA Nephropathy. Journal of the American Society of Nephrology, 22, 1795-1803. https://doi.org/10.1681/ASN.2011050464
|
[14]
|
Fellström, B.C., Barratt, J., Cook, H., et al. (2017) Target-ed-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial. The Lancet, 389, 2117-2127.
https://doi.org/10.1016/S0140-6736(17)30550-0
|
[15]
|
Sallustio, F., Curci, C., Chaoul, N., et al. (2021) High Levels of Gut-Homing Immunoglobulin A+ B Lymphocytes Support the Pathogenic Role of Intestinal Mucosal Hyperrespon-siveness in Immunoglobulin A Nephropathy Patients. Nephrology Dialysis Transplantation, 36, 1765. https://doi.org/10.1093/ndt/gfaa344
|
[16]
|
Zhong, Z.X., Tan, J.X., Tan, L., et al. (2020) Modifications of Gut Micro-biota Are Associated with the Severity of IgA Nephropathy in the Chinese Population. International Immunopharma-cology, 89, Article ID: 107085.
https://doi.org/10.1016/j.intimp.2020.107085
|
[17]
|
Chemouny, J.M., Gleeson, P.J., Abbad, L., et al. (2019) Modu-lation of the Microbiota by Oral Antibiotics Treats Immunoglobulin A Nephropathy in Humanized Mice. Nephrology Di-alysis Transplantation, 34, 1135-1144.
https://doi.org/10.1093/ndt/gfy323
|
[18]
|
Lafayette, R.A., Canetta, P.A., Rovin, B.H., et al. (2017) A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American So-ciety of Nephrology, 28, 1306-1313.
https://doi.org/10.1681/ASN.2016060640
|
[19]
|
Hartono, C., Chung, M., Perlman, A.S., et al. (2018) Bortezomib for Reduction of Proteinuria in IgA Nephropathy. Kidney International Reports, 3, 861-866. https://doi.org/10.1016/j.ekir.2018.03.001
|
[20]
|
Takahara, M., Nagato, T., Nozaki, Y., et al. (2019) A Prolifera-tion-Inducing Ligand (APRIL) Induced Hyper-Production of IgA from Tonsillar Mononuclear Cells in Patients with IgA Nephropathy. Cellular Immunology, 341, Article ID: 103925. https://doi.org/10.1016/j.cellimm.2019.103925
|
[21]
|
Baert, L., Manfroi, B., Casez, O., et al. (2018) The Role of APRIL—a Proliferation Inducing Ligand—in Autoimmune Diseases and Expectations from Its Targeting. Journal of Autoimmunity, 95, 179-190.
https://doi.org/10.1016/j.jaut.2018.10.016
|
[22]
|
Dörner, T., Kinnman, N. and Tak, P.P. (2010) Targeting B Cells in Immune-Mediated Inflammatory Disease: A Comprehensive Review of Mechanisms of Action and Identification of Bi-omarkers. Pharmacology & Therapeutics, 125, 464-475. https://doi.org/10.1016/j.pharmthera.2010.01.001
|
[23]
|
Samy, E., Wax, S., Huard, B., et al. (2017) Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases. International Reviews of Im-munology, 36, 3-19.
https://doi.org/10.1080/08830185.2016.1276903
|
[24]
|
Shabgah, A.G., Shariati-Sarabi, Z., Tavakkol-Afshari, J., et al. (2019) The Role of BAFF and APRIL in Rheumatoid Arthritis. Journal of Cellular Physiology, 234, 17050-17063. https://doi.org/10.1002/jcp.28445
|
[25]
|
Barratt, J., Tumlin, J., Suzuki, Y., et al. (2022) Randomized Phase II JANUS Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria. Kidney International Reports, 7, 1831-1841.
https://doi.org/10.1016/j.ekir.2022.05.017
|
[26]
|
Mathur, M., Barratt, J., Suzuki, Y., et al. (2022) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG Monoclonal Anti-body, in Healthy Volunteers. Kidney International Reports, 7, 993-1003. https://doi.org/10.1016/j.ekir.2022.01.1073
|
[27]
|
Stefan, G. and Mircescu, G. (2021) Hydroxychloroquine in IgA Nephropathy: A Systematic Review. Renal Failure, 43, 1520-1527. https://doi.org/10.1080/0886022X.2021.2000875
|
[28]
|
Liu, L.-J., Yang, Y.-Z., Shi, S.-F., et al. (2019) Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 74, 15-22.
https://doi.org/10.1053/j.ajkd.2019.01.026
|
[29]
|
Poppelaars, F., Faria, B., Schwaeble, W. and Daha, M.R. (2021) The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases? Journal of Clinical Medicine 10, Article No. 4715. https://doi.org/10.3390/jcm10204715
|
[30]
|
Rosenblad, T., Rebetz, J., Johansson, M., et al. (2014) Eculizumab Treatment for Rescue of Renal Function in IgA Nephropathy. Pediatric Nephrology, 29, 2225-2228. https://doi.org/10.1007/s00467-014-2863-y
|
[31]
|
Ring, T., Pedersen, B.B., Salkus, G., et al. (2015) Use of Eculi-zumab in Crescentic IgA Nephropathy: Proof of Principle and Conundrum? Clinical Kidney Journal, 8, 489-491. https://doi.org/10.1093/ckj/sfv076
|
[32]
|
Lafayette, R.A., Rovin, B.H., Reich, H.N., et al. (2020) Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney International Reports, 5, 2032-2041.
https://doi.org/10.1016/j.ekir.2020.08.003
|
[33]
|
Sano, R., Shinozaki, Y. and Ohta, T. (2020) Sodium-Glucose Co-transporters: Functional Properties and Pharmaceutical Potential. Journal of Diabetes Investigation, 11, 770-782. https://doi.org/10.1111/jdi.13255
|
[34]
|
Barratt, J. and Floege, J. (2021) SGLT-2 Inhibition in IgA Nephropathy: The New Standard of Care? Kidney International, 100, 24-26. https://doi.org/10.1016/j.kint.2021.04.002
|
[35]
|
Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 383, 1436-1446. https://doi.org/10.1056/NEJMoa2024816
|
[36]
|
Wheeler, D.C., Toto, R.D., Stefánsson, B.V., et al. (2021) A Pre-Specified Analysis of the DAPA-CKD Trial Demonstrates the Effects of Dapagliflozin on Major Adverse Kidney Events in Patients with IgA Nephropathy. Kidney International, 100, 215-224. https://doi.org/10.1016/j.kint.2021.03.033
|
[37]
|
Li, Y., Wan, Q., Lan, Z.X., et al. (2022) Efficacy and Indications of Tonsillectomy in Patients with IgA Nephropathy: A Retrospective Study. PeerJ, 10, e14481. https://doi.org/10.7717/peerj.14481
|